Together with the assessment by the Medicines Council of the added clinical value, the analyses form the basis for price negotiations with the supplier.
Amgros reports the results of the assessments of the financial analyses to the Medicines Council.
Go to Amgros’ reports on new pharmaceuticals. (Only available in Danish).
When we have received replies to our questions and carried out any adjustments, we report the results of analyses. These reports follows the format in the:
Applicants can draw inspiration from the same template for their cost analyses. We publish our report after the decision on the recommendation by the Danish Medicines Council.
Amgros is independent and objective when we conduct health economic assessments.
We always focus on being professional and transparent in what we do.
We also place high demands on the validity and professional quality of our assessments. It is crucial that we have the latest and most objective knowledge in the area.
In this way, we can ensure that all suppliers receive uniform and professionally based assessment of their products.
Negotiation of prices
When the Danish Medicines Council has determined the added clinical value of a new pharmaceutical, Amgros will negotiate with the applicantREAD MORE
If a new drug is to be considered as a standard treatment at Danish public hospitals, the Danish Medicines Council has to assess it first.READ MORE
I’m responsible for operation and development of business intelligence and health economics. I make sure that our department can proudly claim to be the partner who gets things done.